drugset / Trial / NCT02245451

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

NCT02245451

Phase 1 Completed 15 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to characterise the effects of tipranavir 500 mg and ritonavir 200 mg (TPV/r; given twice daily) at steady-state on the pharmacokinetics of methadone administered as a single dose in healthy adult volunteers

Timeline

Start
2005-01
Primary completion
2005-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Methadone Other / unclassified
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg

Indications

No indication recorded.